scholarly journals Staff Perception of Tobacco Control and Prevention Policy in a Children's Hospital

2020 ◽  
Vol 2020 (1) ◽  
Author(s):  
Y. Li ◽  
J. Holstein ◽  
S. Ziniel ◽  
B. Liu ◽  
K. Wilson
2016 ◽  
Vol 91 ◽  
pp. S16-S22 ◽  
Author(s):  
Muhammad Jami Husain ◽  
Lorna McLeod English ◽  
Nivo Ramanandraibe

2019 ◽  
Vol 45 (1) ◽  
Author(s):  
L. Nicolosi ◽  
C. Rizzo ◽  
G. Castelli Gattinara ◽  
N. Mirante ◽  
E. Bellelli ◽  
...  

Abstract Background Invasive meningococcal disease is a serious global health threat in the world; in 2016, the European Centre for Disease Control and Prevention reported 3280 confirmed cases (including 304 deaths) of Invasive Meningococcal Diseases in Europe. In Italy, in 2017 were reported 200 cases 41% of which due to menB serogroup. From January 2013 the European Medicines Agency (EMA) has authorized the marketing of the meningococcal B vaccine 4CMenB. Methods The study aimed to evaluate and complement the safety profile of 4CMenB in high risk children accessing the vaccine service of the Bambino Gesù Children’s Hospital. All individuals aged six weeks or more receiving the meningococcal 4CMenB (Bexsero®) vaccine that approached the vaccine Centre at the Bambino Gesù Children’s Hospital in Rome, were asked to participate. All parents or caregivers of vaccinated individuals in the study period, were recruited and requested to answer to a questionnaire on adverse events following immunization (AEFI) observed after 7 days, starting from the date of vaccination. Results During the study period (October 2016–October 2017), we collected 157 completed questionnaires (out of 200 distributed). Of those 132 were first doses and 25 were booster administered doses. The median age of the study population was 4.5 years (range 0.29 to 26.8 years), the majority of subjects were high-risk individuals (64%) with chronic health conditions. Overall, 311 adverse events were reported in the 7 days after vaccine administration. In particular 147 events (47%) after administration of first dose and 58 (19%) after the booster doses. A large majority of those events, were of little clinical importance and concentrated in the 24 h after vaccine administration. No hospitalizations or Emergency Department access were reported. Conclusions Results of our study demonstrated that the Bexsero® vaccine is almost well tolerated, with a low incidence of severe AEFIs. Our results also shown that the occurrence of AEFIs is similar within healthy and high risk children.


2008 ◽  
Vol 18 (2) ◽  
pp. 76-86 ◽  
Author(s):  
Lauren Hofmann ◽  
Joseph Bolton ◽  
Susan Ferry

Abstract At The Children's Hospital of Philadelphia (CHOP) we treat many children requiring tracheostomy tube placement. With potential for a tracheostomy tube to be in place for an extended period of time, these children may be at risk for long-term disruption to normal speech development. As such, speaking valves that restore more normal phonation are often key tools in the effort to restore speech and promote more typical language development in this population. However, successful use of speaking valves is frequently more challenging with infant and pediatric patients than with adult patients. The purpose of this article is to review background information related to speaking valves, the indications for one-way valve use, criteria for candidacy, and the benefits of using speaking valves in the pediatric population. This review will emphasize the importance of interdisciplinary collaboration from the perspectives of speech-language pathology and respiratory therapy. Along with the background information, we will present current practices and a case study to illustrate a safe and systematic approach to speaking valve implementation based upon our experiences.


Author(s):  
Patrick J. McGrath ◽  
Garry Johnson ◽  
John T. Goodman ◽  
John Schillinger ◽  
Jennifer Dunn ◽  
...  

2018 ◽  
Author(s):  
Anne E. Kazak ◽  
Wei-Ting Hwang ◽  
Fang Fang Chen ◽  
Martha A. Askins ◽  
Olivia Carlson ◽  
...  

Endoscopy ◽  
2006 ◽  
Vol 39 (S 1) ◽  
Author(s):  
A Pane ◽  
P De Angelis ◽  
F Torroni ◽  
T Caldaro ◽  
G Federici ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document